Skip to main content

CORRECTION article

Front. Oncol., 13 January 2023
Sec. Genitourinary Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1125641

Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer

This article is a correction to:

  1. MRI radiomics predicts progression-free survival in prostate cancer

    1. Read original article
Yushan JiaYushan Jia1Shuai QuanShuai Quan2Jialiang RenJialiang Ren2Hui Wu*Hui Wu3*Aishi Liu*Aishi Liu3*Yang GaoYang Gao3Fene HaoFene Hao3Zhenxing YangZhenxing Yang3Tong ZhangTong Zhang1He HuHe Hu1
  • 1Affiliated Hospital, Inner Mongolia Medical University, Hohhot, China
  • 2Department of Pharmaceuticals Diagnosis, GE Healthcare (China), Shanghai, China
  • 3Department of Radiology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China

A corrigendum on
MRI radiomics predicts progression-free survival in prostate cancer.

by Jia Y, Quan S, Ren J, Wu H, Liu A, Gao Y, Hao F, Yang Z, Zhang T and Hu H (2023) Front. Oncol. 12:974257. doi: 10.3389/fonc.2022.974257

In the published article, there was an error in affiliation 3. Instead of “Department of Radiology, Inner Mongolia International Hospital, Hohhot, China”, it should be “Department of Radiology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: prostate cancer, radiomics, progression-free survival, magnetic resonance imaging, predictions

Citation: Jia Y, Quan S, Ren J, Wu H, Liu A, Gao Y, Hao F, Yang Z, Zhang T and Hu H (2023) Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer. Front. Oncol. 12:1125641. doi: 10.3389/fonc.2022.1125641

Received: 16 December 2022; Accepted: 30 December 2022;
Published: 13 January 2023.

Edited and Reviewed by:

Matteo Ferro, European Institute of Oncology (IEO), Italy

Copyright © 2023 Jia, Quan, Ren, Wu, Liu, Gao, Hao, Yang, Zhang and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hui Wu, terrywuhui@sina.com; Aishi Liu, liuaishi@sina.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.